Definitive Healthcare (NASDAQ:DH) Releases FY 2026 Earnings Guidance

Definitive Healthcare (NASDAQ:DH - Get Free Report) updated its FY 2026 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 0.160-0.19 for the period, compared to the consensus estimate of 0.140. The company issued revenue guidance of $220.0 million-$226.0 million, compared to the consensus revenue estimate of $223.5 million. Definitive Healthcare also updated its Q2 2026 guidance to 0.030-0.040 EPS.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the company. Weiss Ratings restated a "sell (d-)" rating on shares of Definitive Healthcare in a research note on Wednesday, January 21st. Barclays lowered their price objective on Definitive Healthcare from $2.75 to $1.00 and set an "underweight" rating on the stock in a research report on Monday, March 30th. Canaccord Genuity Group lowered their price objective on Definitive Healthcare from $4.00 to $3.00 and set a "hold" rating on the stock in a research report on Friday, February 27th. Zacks Research raised Definitive Healthcare from a "strong sell" rating to a "hold" rating in a research report on Tuesday, April 28th. Finally, Stephens lowered their price objective on Definitive Healthcare from $3.00 to $2.00 and set an "equal weight" rating on the stock in a research report on Friday, February 27th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, five have issued a Hold rating and three have assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $3.27.

Definitive Healthcare Price Performance

NASDAQ DH traded down $0.02 during trading hours on Thursday, reaching $0.92. The company's stock had a trading volume of 331,909 shares, compared to its average volume of 354,274. The firm's 50-day moving average price is $1.10 and its 200-day moving average price is $1.99. The company has a quick ratio of 1.64, a current ratio of 1.64 and a debt-to-equity ratio of 0.41. Definitive Healthcare has a 1 year low of $0.90 and a 1 year high of $4.70. The company has a market capitalization of $97.23 million, a price-to-earnings ratio of -0.74, a PEG ratio of 84.12 and a beta of 1.34.

Definitive Healthcare (NASDAQ:DH - Get Free Report) last posted its quarterly earnings results on Thursday, May 7th. The company reported $0.06 EPS for the quarter, topping analysts' consensus estimates of $0.03 by $0.03. Definitive Healthcare had a positive return on equity of 2.63% and a negative net margin of 57.52%.The company had revenue of $55.93 million for the quarter, compared to analysts' expectations of $55.02 million. Definitive Healthcare has set its Q2 2026 guidance at 0.030-0.040 EPS and its FY 2026 guidance at 0.160-0.19 EPS. On average, equities research analysts predict that Definitive Healthcare will post 0.01 EPS for the current fiscal year.

Institutional Trading of Definitive Healthcare

A number of large investors have recently added to or reduced their stakes in DH. Raymond James Financial Inc. bought a new stake in Definitive Healthcare in the 2nd quarter worth approximately $32,000. Schonfeld Strategic Advisors LLC bought a new stake in Definitive Healthcare in the 4th quarter worth approximately $35,000. HRT Financial LP bought a new stake in Definitive Healthcare in the 4th quarter worth approximately $47,000. ExodusPoint Capital Management LP bought a new stake in Definitive Healthcare in the 4th quarter worth approximately $47,000. Finally, Bayesian Capital Management LP bought a new stake in Definitive Healthcare in the 2nd quarter worth approximately $55,000. Institutional investors own 98.67% of the company's stock.

About Definitive Healthcare

Definitive Healthcare NASDAQ: DH is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.

The company's flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.